company background image
LUMO

Lumos Pharma NasdaqGM:LUMO Stock Report

Last Price

US$7.71

Market Cap

US$64.5m

7D

7.8%

1Y

-22.9%

Updated

29 Jun, 2022

Data

Company Financials +
LUMO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LUMO Stock Overview

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases.

Lumos Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lumos Pharma
Historical stock prices
Current Share PriceUS$7.71
52 Week HighUS$11.52
52 Week LowUS$6.15
Beta1.02
1 Month Change-1.78%
3 Month Change-17.98%
1 Year Change-22.90%
3 Year Changen/a
5 Year Changen/a
Change since IPO-11.99%

Recent News & Updates

Mar 22
Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

LUMOUS BiotechsUS Market
7D7.8%3.8%1.6%
1Y-22.9%-25.8%-20.8%

Return vs Industry: LUMO exceeded the US Biotechs industry which returned -26.1% over the past year.

Return vs Market: LUMO underperformed the US Market which returned -20.4% over the past year.

Price Volatility

Is LUMO's price volatile compared to industry and market?
LUMO volatility
LUMO Average Weekly Movement7.4%
Biotechs Industry Average Movement13.1%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: LUMO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: LUMO's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a32Rick Hawkinshttps://www.lumos-pharma.com

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Lumos Pharma Fundamentals Summary

How do Lumos Pharma's earnings and revenue compare to its market cap?
LUMO fundamental statistics
Market CapUS$64.53m
Earnings (TTM)-US$29.52m
Revenue (TTM)US$341.00k

189.2x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LUMO income statement (TTM)
RevenueUS$341.00k
Cost of RevenueUS$0
Gross ProfitUS$341.00k
Other ExpensesUS$29.86m
Earnings-US$29.52m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.53
Gross Margin100.00%
Net Profit Margin-8,656.60%
Debt/Equity Ratio0%

How did LUMO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is LUMO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LUMO?

Other financial metrics that can be useful for relative valuation.

LUMO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does LUMO's PB Ratio compare to its peers?

LUMO PB Ratio vs Peers
The above table shows the PB ratio for LUMO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.5x
DBTX Decibel Therapeutics
0.7x-24.5%US$95.3m
ORGS Orgenesis
1.8x148.5%US$62.5m
EFTR eFFECTOR Therapeutics
2.4x-38.7%US$60.9m
MTEM Molecular Templates
1.2x-5.7%US$55.0m
LUMO Lumos Pharma
0.8x1.8%US$64.5m

Price-To-Book vs Peers: LUMO is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (1.5x).


Price to Earnings Ratio vs Industry

How does LUMO's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: LUMO is good value based on its Price-To-Book Ratio (0.8x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is LUMO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LUMO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LUMO's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of LUMO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LUMO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LUMO's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LUMO's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Lumos Pharma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


1.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LUMO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LUMO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LUMO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LUMO's revenue (86.4% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: LUMO's revenue (86.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LUMO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Lumos Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-31.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LUMO is currently unprofitable.

Growing Profit Margin: LUMO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LUMO is unprofitable, and losses have increased over the past 5 years at a rate of 31% per year.

Accelerating Growth: Unable to compare LUMO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LUMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: LUMO has a negative Return on Equity (-36.08%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Lumos Pharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LUMO's short term assets ($92.6M) exceed its short term liabilities ($5.2M).

Long Term Liabilities: LUMO's short term assets ($92.6M) exceed its long term liabilities ($6.1M).


Debt to Equity History and Analysis

Debt Level: LUMO is debt free.

Reducing Debt: LUMO had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LUMO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: LUMO has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 32% each year.


Discover healthy companies

Dividend

What is Lumos Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LUMO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LUMO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LUMO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LUMO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LUMO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Rick Hawkins (72 yo)

11.42yrs

Tenure

US$1,353,439

Compensation

Mr. Richard J. Hawkins, also known as Rick, is the Founder of Lumos Pharma, Inc. and has been its Chairman of the Board since March 26, 2020, its Chief Executive Officer since January 2011 and served as it...


CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD1.35M) is above average for companies of similar size in the US market ($USD759.63K).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: LUMO's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: LUMO's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Lumos Pharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Lumos Pharma, Inc.
  • Ticker: LUMO
  • Exchange: NasdaqGM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$64.527m
  • Shares outstanding: 8.37m
  • Website: https://www.lumos-pharma.com

Number of Employees


Location

  • Lumos Pharma, Inc.
  • 4200 Marathon Boulevard
  • Suite 200
  • Austin
  • Texas
  • 78756
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.